Kardos monotherapy allows attaining the target levels of systolic and diastolic blood pressure in patients with high-risk and very-high-risk hypertension. We demonstrated excellent tolerability of the preparation in combination with reliable blood pressure decrease over 24 h, during day and night hours.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
E. A. Zernyukova, Comparative Effi ciency and Pharmacodynamics of a Preparation of the Basis of Ultralow Doses of Antibodies to C-Terminal Fragment of AT1 Receptor of Angiotensin II, ACE Inhibitors, and Blockers of Angiotensin II Receptors in Patients with Essential Hypertension. Author’s Synopsis of Cand Med. Sci. Dissertation, Volgograd (2005), p. 24.
A. V. Nazvanova, Experimental Substantiation of Kardos Administration in the Therapy of Essential Hypertension and Chronic Heart Failure. Author’s Synopsis of Cand Med. Sci. Dissertation, Volgograd (2006), p. 26.
O. I. Epshtein, A. V. Martyushev, D. R. Kudryashova, et al., Byull. Eksp. Biol. Med., Suppl. 4, 69-72 (2002).
S. Julius, S. D. Nesbitt, B. M. Egan, et al., N. Engl. J. Med., 354, No. 16, 1685-1697 (2006).
J. Lopez-Sendon, K. Swedberg, J. McMurray, et al., Eur. Heart. J. 25, No. 16, 1454-1470 (2004).
Author information
Authors and Affiliations
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 148, Suppl. 1, pp. 80-82, August, 2009
Rights and permissions
About this article
Cite this article
Petrov, V.I., Nedogoda, S.V., Epshtein, O.I. et al. The Use of Ultralow Doses of Antibodies to C-Terminal Fragment of Angiotensin II AT1 Receptor (Kardos) in the Therapy of Arterial Hypertension. Bull Exp Biol Med 148, 332 (2009). https://doi.org/10.1007/s10517-009-0686-9
Received:
Published:
DOI: https://doi.org/10.1007/s10517-009-0686-9